Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Azilsartan: Azilsartan in group I 40-80mg for a period of 8 weeks
Control Intervention1: telmisartan: telmisartan for group II in a dose of 40-80mg over a period of 8 weeks
Sponsors
Department of Pharmacology
Eligibility
Inclusion criteria
Inclusion criteria: 1. New patients with hypertension i.e not on any antihypertensive therapy. 2. Adult males and females of age 21 years or more.
Exclusion criteria
Exclusion criteria: 1. Patients already on anti-hypertensives. 2. Patients with hypersensitivity to AZL or telmisartan. 3. Pregnant/ lactating women/ women planning to conceive. 4. Evidence of severe renal disorder. 5. Patients with hepatic insufficiencies. 6. Patients unwilling or unable to comply with the study proceedings. 7. Patients with severe bradycardia, cardiogenic shock, heart block, sick sinus syndrome, decompensated heart failure, bronchial asthma, hypothyroidism, CVA, CAD. 8. Patients with other co morbidities like hyperthyroidism, anxiety disorders. 9. Patients with refractory hypertension.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in blood pressure of patients of hypertension on azilsartan versus telmisartanTimepoint: baseline, 4week and 8weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| to monitor the side effects of both azilsartan and telmisartan in hypertensive patientsTimepoint: 6weeks | — |
Countries
India
Contacts
Public ContactEna Bhajni
GMC Patiala
Outcome results
None listed